These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 29907857

  • 1. Alterations of mTOR signaling impact metabolic stress resistance in colorectal carcinomas with BRAF and KRAS mutations.
    Fritsche-Guenther R, Zasada C, Mastrobuoni G, Royla N, Rainer R, Roßner F, Pietzke M, Klipp E, Sers C, Kempa S.
    Sci Rep; 2018 Jun 15; 8(1):9204. PubMed ID: 29907857
    [Abstract] [Full Text] [Related]

  • 2. p53-armed oncolytic adenovirus induces autophagy and apoptosis in KRAS and BRAF-mutant colorectal cancer cells.
    Tamura S, Tazawa H, Hori N, Li Y, Yamada M, Kikuchi S, Kuroda S, Urata Y, Kagawa S, Fujiwara T.
    PLoS One; 2023 Jun 15; 18(11):e0294491. PubMed ID: 37972012
    [Abstract] [Full Text] [Related]

  • 3. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
    Goulielmaki M, Koustas E, Moysidou E, Vlassi M, Sasazuki T, Shirasawa S, Zografos G, Oikonomou E, Pintzas A.
    Oncotarget; 2016 Feb 23; 7(8):9188-221. PubMed ID: 26802026
    [Abstract] [Full Text] [Related]

  • 4. Pro-survival responses to the dual inhibition of anti-apoptotic Bcl-2 family proteins and mTOR-mediated signaling in hypoxic colorectal carcinoma cells.
    Risberg K, Redalen KR, Sønstevold L, Bjørnetrø T, Sølvernes J, Ree AH.
    BMC Cancer; 2016 Jul 26; 16():531. PubMed ID: 27461218
    [Abstract] [Full Text] [Related]

  • 5. Common and mutation specific phenotypes of KRAS and BRAF mutations in colorectal cancer cells revealed by integrative -omics analysis.
    Kundu S, Ali MA, Handin N, Conway LP, Rendo V, Artursson P, He L, Globisch D, Sjöblom T.
    J Exp Clin Cancer Res; 2021 Jul 07; 40(1):225. PubMed ID: 34233735
    [Abstract] [Full Text] [Related]

  • 6. Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer.
    Wan XB, Wang AQ, Cao J, Dong ZC, Li N, Yang S, Sun MM, Li Z, Luo SX.
    World J Gastroenterol; 2019 Feb 21; 25(7):808-823. PubMed ID: 30809081
    [Abstract] [Full Text] [Related]

  • 7. BRAF V600E inhibition stimulates AMP-activated protein kinase-mediated autophagy in colorectal cancer cells.
    Sueda T, Sakai D, Kawamoto K, Konno M, Nishida N, Koseki J, Colvin H, Takahashi H, Haraguchi N, Nishimura J, Hata T, Takemasa I, Mizushima T, Yamamoto H, Satoh T, Doki Y, Mori M, Ishii H.
    Sci Rep; 2016 Jan 11; 6():18949. PubMed ID: 26750638
    [Abstract] [Full Text] [Related]

  • 8. Switch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell lines.
    Malaguarnera R, Chen KY, Kim TY, Dominguez JM, Voza F, Ouyang B, Vundavalli SK, Knauf JA, Fagin JA.
    J Clin Endocrinol Metab; 2014 Oct 11; 99(10):E1976-87. PubMed ID: 25029414
    [Abstract] [Full Text] [Related]

  • 9. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF.
    Oncotarget; 2017 Feb 07; 8(6):9251-9266. PubMed ID: 27999210
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Localization of active, dually phosphorylated extracellular signal-regulated kinase 1 and 2 in colorectal cancer with or without activating BRAF and KRAS mutations.
    Holck S, Bonde J, Pedersen H, Petersen AA, Chaube A, Nielsen HJ, Larsson LI.
    Hum Pathol; 2016 Aug 07; 54():37-46. PubMed ID: 27036313
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Specific activation of glycolytic enzyme enolase 2 in BRAF V600E-mutated colorectal cancer.
    Yukimoto R, Nishida N, Hata T, Fujino S, Ogino T, Miyoshi N, Takahashi H, Uemura M, Satoh T, Hirofumi Y, Mizushima T, Doki Y, Eguchi H.
    Cancer Sci; 2021 Jul 07; 112(7):2884-2894. PubMed ID: 33934428
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Crenolanib Regulates ERK and AKT/mTOR Signaling Pathways in RAS/BRAF-Mutated Colorectal Cancer Cells and Organoids.
    Fujino S, Miyoshi N, Ito A, Yasui M, Ohue M, Ogino T, Takahashi H, Uemura M, Matsuda C, Mizushima T, Doki Y, Eguchi H.
    Mol Cancer Res; 2021 May 07; 19(5):812-822. PubMed ID: 33579816
    [Abstract] [Full Text] [Related]

  • 19. Concomitant BRAF and PI3K/mTOR blockade is required for effective treatment of BRAF(V600E) colorectal cancer.
    Coffee EM, Faber AC, Roper J, Sinnamon MJ, Goel G, Keung L, Wang WV, Vecchione L, de Vriendt V, Weinstein BJ, Bronson RT, Tejpar S, Xavier RJ, Engelman JA, Martin ES, Hung KE.
    Clin Cancer Res; 2013 May 15; 19(10):2688-98. PubMed ID: 23549875
    [Abstract] [Full Text] [Related]

  • 20. Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance.
    Morkel M, Riemer P, Bläker H, Sers C.
    Oncotarget; 2015 Aug 28; 6(25):20785-800. PubMed ID: 26299805
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.